Treatment of alopecia areata: Modern principles and perspectives;Liječen je alopecije areate: Suvremeni principi i perspektive

Lijecnicki Vjesnik

Volumn 132, Issue 11-12, 2010, Pages 365-369

  Brajac, Ines ^a   Kaštelan, Marija ^a   Periša, Darinka ^a   Simonić, Edita ^a   Stojnić SOŠA, Lilijana ^a   Massari, Larisa Prpić ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Adrenal cortex hormones Therapeutic use; Alopecia areata Drug therapy, immunology, pathology; Immunotherapy Methods; Photochemotherapy

Indexed keywords

ALOPECIA AREATA; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ALOPECIA AREATA; HUMANS;

EID: 78951470765     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Price VH. Alopecia areata: Clinical aspects. J Invest Dermatol 1991; 96: 68.
2. Alkhalifah A, Alsantali A, Wang E. McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010; 62: 2177-88.
3. Garg S, Messenger AG. Alopecia Areata: Evidence-Based Treatments. Sem Cutan Med Surg 2009; 28: 15-8.
4. Shapiro J, Madani S. Alopecia areata: diagnosis and managment. Inter J Dermatol 1999; 38: 19S-24S.
5. Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Internal J Dermatol 1996; 35: 133-6.
6. Tan E, Tay YK, Giam YC. A clinical study of childhood alopecia areata in Singapore. Pediatric Dermatol 2002; 19: 298-301.
7. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49: 96-8.
8. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006; 20: 1243-7.
9. Ross EK, Shapiro J. Management of hair loss. Dermatol Clin 2005; 23: 227-43.
10. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42: 549-66.
11. Price VH. Treatment of hair loss. New Engl J Med 1999; 341: 964-73.
12. Porter D, Burton JL. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971; 85: 272-73.
13. Sohn KC, Jang S, Choi DK i sur. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem Biophys Res Commun 2007; 356: 810-15.
14. Shapiro J, Harvey L, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: A clinic and immunopathologic evaluation. J Am Acad Dermatol 1997; 36: 114-7.
15. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005; 52: 287-90.
16. Assouly P, Reygagne P, Jouanique C i sur. Intravenous pulse methylprednisolone therapy for severe alopecia areata. An open study of 66 patients. Ann Dermatol Venereol 2003; 130: 326-30.
17. Kurosawa M, Nakagawa S, Mizuashi M i sur. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006; 212: 361-5.
18. Friedli A, Labarthe MP, Engelhardt E i sur. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998; 39: 597-602.
19. Ito T, Aoshima M, Ito N i sur. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch Dermatol Res 2009; 301: 73-80.
20. Holzer AM, Kaplan LL, Levis WR. Haptens as drugs: contact allergens are powerful topical immunomodulators. J Drugs Dermatol 2006; 5: 410-6.
21. Brocker EB, Echternacht-Happle K. Hamm H i sur. Abnormal expression of class I and class II majorhistocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol 1987; 88: 564-8.
22. Tosti A, Duque-Estrada B. Treatment strategies for alopecia. Expert Opin Pharmacother 2009; 10: 1017-26.
23. McMichael AJ. Henderson RL. Topical sensitizers in alopecia areata. Dermatol Nurs 2004; 16: 333-6.
24. Perret CM, Steijlen PM, Zaun H, Happle R. Erythema multiforme-like eruptions: a rare side effect topical immunotherapy with diphenylcyclopropenone. Dermatologica 1990; 180: 5-7.
25. Duhra P, Foulds IS. Persistent vitiligo induced by diphencyprone. Br J Dermatol 1990; 123: 415-6.
26. Kratka J, Goerz G, Vizethum W i sur. Dinitrochlorobenzene: influence on the cytochrome P450 system and mutagenic effects. Arch Dermatol Res 1979; 266: 315-8.
27. Strobel R, Rohrborn G. Mutagenic cell transforming activities 1-chlor2, 4-dinitrobenzene (DNCB) squaric acid-dibutylester (SADBE) Arch Toxicol 1980; 45: 307-14.
28. Van der Steen PH, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin 1993; 11: 619-622.
29. Galadari I, Rubaie S, Alkaabi J, Galadari H. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata. Eur Ann Allergy Clin Immunol 2003; 35: 397-401.
30. Schuttelaar ML, Hamstra JJ, Plinck EP i sur. Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 1996; 135: 581-5.
31. Cotellessa C, Peris K, Caracciolo E i sur. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44: 73-6.
32. Avgerinou G, Gregoriou S, Rigopoulos D, Stratigos A, Kalogeromitros D, Katsambas A. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol 2008; 22: 320-3.
33. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137: 1063-8.
34. Dall'oglio MR, Nasca, ML Musumeci, La Torre G, Ricciardi G, Potenza C. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat 2005; 16: 10-4.
35. Happle R, Bucher U, Kalveram KJ i sur. Contact allergy as a therapeutic tool for alopecia areata: comparison between dinitrochlorobenzene and squaric acid dibutylester. Arch Dermatol Res 1979; 264: 101-2.
36. Tosti A, De Padova MP, Minghetti G i sur. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol 1986; 15: 209-10.
37. Pardasani AG, Turner E, McMichael AJ. Squaric acid dibutylester: indications for use and efficacy in alopecia areata. Arch Dermatol 2001; 137: 970-2.
38. Sasmaz S, Arican O. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol 2005; 6: 403-6.
39. Tang L, Cao L, Sundberg JP, Lui H, Shapiro J. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol 2004; 13: 5-10.
40. Thappa DM, Vijayikumar M. Alopecia areata. Indian J Dermatol Venereol Leprol 2001; 67: 188-9.
41. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987; 123: 1491-3.
42. Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol 1991; 96: 73S-4S.
43. Olsen EA, Dunlap FE, Funicella Ti sur. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377-85.
44. Lucky AW, Piacquadio DJ, Ditre CM i sur. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50: 541-53.
45. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16: 730-6.
46. Fransway AF, Muller SA. Topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. Cutis 1988; 41: 431-5.
47. Olsen EA, Whiting D, Bergfeld i sur. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57: 767-74.
48. Mohamed Z, BhouriA, Jallouli A, Fazaa B, Kamoun MR, Mokhtar M. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol Venereol 2005; 19: 552-5.
49. Alabdulkareem AS, Abahussein AA, Okoro A. Minimal benefit from photochemotherapy for alopecia areata. International J Dermatol 1996; 35: 890-1.
50. Sahin S, Yalcin B, Karduman A. PUVA treatment for alopecia areata: experience in a Turkish population. Dermatology 1998; 197: 245-7.
51. Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: Audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995; 133: 914-8.
52. Healy E, Rogers S. PUVA treatment for alopecia areata - does it work? A retrospective review of 102 cases. Br J Dermatol 1993; 129: 42-4.
53. Ree K. Reduction of Langerhans cells in human epidermis during PUVA therapy: a morphometric study. J Invest Dermatol 1982; 78: 488-92.
54. Verma DD, Verma S, McElwee KJ, Freyschmidt-Paul P, Hoffman R, Fahr A. Treatment of alopecia areata in the DEBR model using cyclosporin A lipid vesicles. Eur J Dermatol 2004; 14: 332-8.
55. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997; 36: 114-7.
56. Kim BJ, Min SU, Park KY i sur. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat 2008; 19: 216-20.
57. Phillips MA, Graves JE, Nunley JR. Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine. J Am Acad Dermatol 2005; 53(1): S252-S5.
58. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-38.
59. Wasserman D, Guzman-Sanchez D, Scott K i sur. Alopecia areata. I Jour Dermatol 2007; 46: 121-31.
60. Ettefagh L, Neodorost S, Mirmirani P. Alopecia areta in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004; 140: 1012.
61. Strober BE, Siu K, Alexis AF i sur. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005; 52: 1082-1.
62. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005; 141: 759-60.
63. O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009; 3: 159-68.
64. MacDonald SP, Wood ML, Hutchinson PE. Sladden M. Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149: 692-9.
65. Barankin B, Taher M, Wasel N. Successful hair transplant of eyebrow alopecia areata. J Cutan Medical Surg 2006; 2: 9.
66. Garg G, Thami GP. Micropigmentation: tattooing for medical purposes. Dermatol Surg 2005; 31: 928-31.